Cargando…

National Proficiency Testing of Molecular Diagnostics for Tuberculosis and Drug Resistance Detection — China, 2014–2019

What is already known about this topic? Proficiency testing (PT) is a key component of quality assurance and is essential in ensuring accurate laboratory diagnosis of tuberculosis (TB) and drug-resistant TB. The National Tuberculosis Reference Laboratory (NTRL) developed a novel PT panel to test lab...

Descripción completa

Detalles Bibliográficos
Autores principales: Ou, Xichao, Xia, Hui, Wang, Shengfen, Zhao, Bing, Fan, Jiale, Song, Yuanyuan, Zhou, Yang, Zheng, Yang, Zhao, Yanlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392952/
https://www.ncbi.nlm.nih.gov/pubmed/34594859
http://dx.doi.org/10.46234/ccdcw2021.072
_version_ 1783743621537726464
author Ou, Xichao
Xia, Hui
Wang, Shengfen
Zhao, Bing
Fan, Jiale
Song, Yuanyuan
Zhou, Yang
Zheng, Yang
Zhao, Yanlin
author_facet Ou, Xichao
Xia, Hui
Wang, Shengfen
Zhao, Bing
Fan, Jiale
Song, Yuanyuan
Zhou, Yang
Zheng, Yang
Zhao, Yanlin
author_sort Ou, Xichao
collection PubMed
description What is already known about this topic? Proficiency testing (PT) is a key component of quality assurance and is essential in ensuring accurate laboratory diagnosis of tuberculosis (TB) and drug-resistant TB. The National Tuberculosis Reference Laboratory (NTRL) developed a novel PT panel to test laboratories’ proficiency for molecular TB diagnostic assays throughout the TB laboratory network. A total of 6 PT rounds for molecular diagnostics were conducted by NTRL from 2014 to 2019. What is added by this report? PT conducted using artificial sputum specimens increased from 120 in the first round to 1,835 in the sixth round. Overall, laboratories demonstrated good proficiency for MTB and drug-resistance detection by molecular diagnostics, which is evident from the qualification rates over the six rounds: 95%, 97%, 96%, 93%, 93%, and 97%, respectively. What are the implications for public health practice? The use of artificial sputum specimens for PT panel production to test TB molecular diagnostics in China is feasible. Most of the participating laboratories provided reliable molecular diagnostic results for MTB and drug-resistance detection. The TB laboratory network can be instrumental in implementing PT expansion and improving the quality of TB molecular diagnosis in China.
format Online
Article
Text
id pubmed-8392952
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-83929522021-09-29 National Proficiency Testing of Molecular Diagnostics for Tuberculosis and Drug Resistance Detection — China, 2014–2019 Ou, Xichao Xia, Hui Wang, Shengfen Zhao, Bing Fan, Jiale Song, Yuanyuan Zhou, Yang Zheng, Yang Zhao, Yanlin China CDC Wkly Preplanned Studies What is already known about this topic? Proficiency testing (PT) is a key component of quality assurance and is essential in ensuring accurate laboratory diagnosis of tuberculosis (TB) and drug-resistant TB. The National Tuberculosis Reference Laboratory (NTRL) developed a novel PT panel to test laboratories’ proficiency for molecular TB diagnostic assays throughout the TB laboratory network. A total of 6 PT rounds for molecular diagnostics were conducted by NTRL from 2014 to 2019. What is added by this report? PT conducted using artificial sputum specimens increased from 120 in the first round to 1,835 in the sixth round. Overall, laboratories demonstrated good proficiency for MTB and drug-resistance detection by molecular diagnostics, which is evident from the qualification rates over the six rounds: 95%, 97%, 96%, 93%, 93%, and 97%, respectively. What are the implications for public health practice? The use of artificial sputum specimens for PT panel production to test TB molecular diagnostics in China is feasible. Most of the participating laboratories provided reliable molecular diagnostic results for MTB and drug-resistance detection. The TB laboratory network can be instrumental in implementing PT expansion and improving the quality of TB molecular diagnosis in China. Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2021-03-19 /pmc/articles/PMC8392952/ /pubmed/34594859 http://dx.doi.org/10.46234/ccdcw2021.072 Text en Copyright and License information: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2021 https://creativecommons.org/licenses/by-nc-sa/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/)
spellingShingle Preplanned Studies
Ou, Xichao
Xia, Hui
Wang, Shengfen
Zhao, Bing
Fan, Jiale
Song, Yuanyuan
Zhou, Yang
Zheng, Yang
Zhao, Yanlin
National Proficiency Testing of Molecular Diagnostics for Tuberculosis and Drug Resistance Detection — China, 2014–2019
title National Proficiency Testing of Molecular Diagnostics for Tuberculosis and Drug Resistance Detection — China, 2014–2019
title_full National Proficiency Testing of Molecular Diagnostics for Tuberculosis and Drug Resistance Detection — China, 2014–2019
title_fullStr National Proficiency Testing of Molecular Diagnostics for Tuberculosis and Drug Resistance Detection — China, 2014–2019
title_full_unstemmed National Proficiency Testing of Molecular Diagnostics for Tuberculosis and Drug Resistance Detection — China, 2014–2019
title_short National Proficiency Testing of Molecular Diagnostics for Tuberculosis and Drug Resistance Detection — China, 2014–2019
title_sort national proficiency testing of molecular diagnostics for tuberculosis and drug resistance detection — china, 2014–2019
topic Preplanned Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392952/
https://www.ncbi.nlm.nih.gov/pubmed/34594859
http://dx.doi.org/10.46234/ccdcw2021.072
work_keys_str_mv AT ouxichao nationalproficiencytestingofmoleculardiagnosticsfortuberculosisanddrugresistancedetectionchina20142019
AT xiahui nationalproficiencytestingofmoleculardiagnosticsfortuberculosisanddrugresistancedetectionchina20142019
AT wangshengfen nationalproficiencytestingofmoleculardiagnosticsfortuberculosisanddrugresistancedetectionchina20142019
AT zhaobing nationalproficiencytestingofmoleculardiagnosticsfortuberculosisanddrugresistancedetectionchina20142019
AT fanjiale nationalproficiencytestingofmoleculardiagnosticsfortuberculosisanddrugresistancedetectionchina20142019
AT songyuanyuan nationalproficiencytestingofmoleculardiagnosticsfortuberculosisanddrugresistancedetectionchina20142019
AT zhouyang nationalproficiencytestingofmoleculardiagnosticsfortuberculosisanddrugresistancedetectionchina20142019
AT zhengyang nationalproficiencytestingofmoleculardiagnosticsfortuberculosisanddrugresistancedetectionchina20142019
AT zhaoyanlin nationalproficiencytestingofmoleculardiagnosticsfortuberculosisanddrugresistancedetectionchina20142019